Stifel analyst Paul Matteis reiterated a Hold rating and {REMOVEPT} price target on Alexion Pharmaceuticals (NASDAQ: ALXN)The analyst comments "While ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133August 30, 2019 12:00 PM Alexion (ALXN) Soliris IPR Surprising, But Long-Term Impact 'Limited' - Raymond JamesAugust 30, 2019 10:59 AM Piper Jaffray Defends Alexion Pharmaceuticals (ALXN)August 30, 2019 10:44 AM Alexion Pharmaceuticals (ALXN) PTAB News an 'Incremental Negative' - BairdAugust 30, 2019 10:25 AM Increasing unusual option volume: ALXN COO ULTA DELL AMBA August 30, 2019 10:04 AM Pre-Open 08/30: (SEAC) (AMBA) (MSGN) Higher (ULTA) (AOBC) (ALXN) Lower (more...)August 30, 2019 9:19 AM Alexion Pharma (ALXN) Soliris patents get review on Amgen (AMGN) challenge at patent office - BloombergAugust 30, 2019 8:49 AM Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple SclerosisAugust 28, 2019 8:30 AM Alexion to Present at the 14th Annual Citi Biotech ConferenceAugust 28, 2019 6:30 AM